Skip to main content
. 2021 Mar;62(3):313–318. doi: 10.2967/jnumed.120.243840

FIGURE 3.

FIGURE 3.

(A) Schematic structure of DOTA-PEG4-LLP2A. (B) Biodistribution of 177Lu/68Ga-DOTA-PEG4-LLP2A and survival curves for treatments with 177Lu-DOTA-PEG4-LLP2A alone and combined with immune checkpoint inhibitors. (Reprinted with permission of 38 and 39.)